# Special Issue

## Molecular Biomarkers and More Efficient Therapies for Sepsis

### Message from the Guest Editors

After a pathogen infection, the host deteriorates due to multiple organ dysfunctions, resulting in sepsis. During pathogen invasion, immune cells, platelets, and other host cells join the inflammatory pathophysiology to protect the host. This process contains and destroys pathogens and damages host organs, as it causes severe inflammation. The clinical diagnosis of sepsis depends on the SOFA score calculated from the severity of organ failure. In some cases, the pathogens secrete substances to aid the invasion process. Signal transduction mechanisms and molecular biomarkers released from pathogens or the host during the infection process may help to define sepsis severity and lead to new insights into sepsis diagnosis and therapy. Morbidity and mortality are risks in sepsis with multiple organ dysfunction. Therefore, the biomarkers of sepsis may benefit from early diagnosis and expedited therapeutic interventions to improve the prognosis.

### Guest Editors

Dr. Wen-Lin Su

Dr. Sheng-Kang Chiu

Dr. Chih-Hao Shen

Dr. Yi-Ting Chen

### Deadline for manuscript submissions

closed (30 September 2024)

**Biomedicines**

**an Open Access Journal by MDPI**

**Impact Factor 3.9**
**CiteScore 6.8**
**Indexed in PubMed**

mdpi.com/si/166365

*Biomedicines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

# Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

### Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

### Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).